Neurocrine Biosciences Inc
Research Neurocrine Biosciences Inc (NBIX) on Bullrun: valuation model: 8.2% undervalued, market cap USD 15.58B, P/E 22.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNBIX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal8.2% undervalued
- Market capUSD 15.58B
- P/E22.5
- Financial periodQ2 2026
- RevenueUSD 959.00M
- Net incomeUSD 144.40M
- Free cash flowUSD 128.60M
- Gross margin97.6%
Valuation Snapshot
Bullrun's latest valuation model marks Neurocrine Biosciences Inc as 8.2% undervalued; latest market cap is USD 15.58B; P/E is 22.5.
Peer valuation comparison
Latest P/E is 22.47x versus a Healthcare sector median of 24.46x (8.1% below).
Latest P/E is 22.47x versus a United States median of 24.87x (9.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.86B | USD 478.60M | USD 748.70M | 98.2% | 4.67 | USD 713.00M | USD 415.30M | USD 3.25B |
| FY2024 | USD 2.36B | USD 341.30M | USD 557.20M | 98.6% | 3.29 | USD 233.00M | USD 455.10M | USD 2.59B |
| FY2023 | USD 1.89B | USD 249.70M | USD 361.60M | 97.9% | 2.47 | USD 251.10M | USD 428.40M | USD 2.23B |
| FY2022 | USD 1.49B | USD 154.50M | USD 322.90M | 98.4% | 1.56 | USD 262.90M | USD 265.80M | USD 1.71B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 15.58B | 22.5 | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.20B | 30.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.57B | 41.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 12.95B | 70.5 | n/a | n/a |
| 2022 | 2022-12-30 | USD 11.48B | 205.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.08B | 93.6 | n/a | n/a |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Neurocrine Biosciences Inc overvalued or undervalued?
Bullrun's valuation model currently marks Neurocrine Biosciences Inc as 8.2% undervalued.
What is Neurocrine Biosciences Inc's market cap?
Neurocrine Biosciences Inc's market capitalization is USD 15.58B.
What is Neurocrine Biosciences Inc's P/E ratio?
Neurocrine Biosciences Inc's price-to-earnings (P/E) ratio is 22.5.
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.